Can torque teno virus be a predictor of SARS-CoV-2 disease progression in cancer patients?
J Infect Chemother
; 28(12): 1623-1627, 2022 Dec.
Article
em En
| MEDLINE
| ID: mdl-36007694
ABSTRACT
INTRODUCTION:
Cancer patients with SARS-CoV-2 infection can experience a broad range of clinical manifestations and outcomes. Previous studies have demonstrated an association between torque teno virus (TTV) load and deficiencies of the immune system. The impact of SARS-CoV-2 and TTV viral loads in cancer patients is unknown.METHODS:
In this retrospective study, 157 cancer patients and 191 noncancer controls were analysed for SARS-CoV-2 RNA and TTV DNA presence.RESULTS:
SARS-CoV-2 RNA was detected in 66.2% of cancer patients and in 68.6% of noncancer control subjects. In SARS-CoV-2-positive patients, TTV was detectable in 79.8% of cancer patients, while in controls, TTV was detected in 71.7% of subjects. No statistically significant correlation was found between TTV and SARS-CoV-2 loads in cancer patients. However, the 100-day survival rate in cancer patients who died from COVID-19 was significantly lower in the TTV-positive group than in the TTV-negative group (P = 0.0475). In the cancer TTV-positive group, those who died also had a higher load of TTV than those who did not die (P = 0.0097).CONCLUSIONS:
Our findings indicated that the presence of TTV in nasopharyngeal swabs from cancer patients was related to a higher number of deaths from COVID-19 and to a higher TTV DNA load.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Torque teno virus
/
Infecções por Vírus de DNA
/
COVID-19
/
Neoplasias
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article